p> Amortization of intangible assets 167 46
Income from operations 5,518 5,556
Interest and other (income)/expense, net 380 144
Income before provision for income taxes 5,138 5,412
Provision for income taxes 1,927 2,057
Net income $3,211 $3,355
Net income per common share
Basic $0.29 $0.30
Diluted 0.28 0.30
Weighted average common shares outstanding
Basic 11,123,792 11,015,967
Diluted 11,270,089 11,212,285
NUTRACEUTICAL INTERNATIONAL CORPORATION
EBITDA SCHEDULE
(unaudited; dollars in thousands)
Three months ended December 31,
2007 2006
Net income $3,211 $3,355
Provision for income taxes 1,927 2,057
Interest and other (income)/expense, net (1) 380 144
Depreciation and amortization 1,312 1,101
EBITDA $6,830 $6,657
(1) Includes amortization of deferred financing fees and losses associated
with fixed asset disposals.
'/>"/>SOURCE Nutraceutical International Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related medicine news :1.
Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business2.
NutraCea Forms Joint Ventures With HerbalScience to Develop Nutraceutical Extracts and Pharmaceutical Chemistries From Stabilized Rice Bran3.
Nutraceutical Reports 2007 Fiscal Year End Results4.
New Nutraceutical Supplement Provides Simplified Approach to Diabetes Management Programs5.
New Nutraceutical That Stabilizes Blood Sugar Naturally is Introduced6.
Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share7.
Accuray Reports Continued Growth in Second Quarter of Fiscal 20088.
Cardinal Health Reports Second Quarter Results, Revises EPS Outlook9.
Encision Reports Third Fiscal Quarter Results10.
Zimmer Reports Fourth Quarter and 2007 Financial Results11.
Amylin Pharmaceuticals Reports 2007 Financial Results